FDA Grants Expanded Interchangeability Designation to Yuflyma
Adalimumab-aaty (Yuflyma) prefilled syringes and autoinjectors are now fully interchangeable with the reference product adalimumab (Humira) across marketed dosage forms and strengths.
FDA Approves Roflumilast Foam For Plaque Psoriasis of Scalp, Body
The supplemental new drug application for roflumilast (Zoryve) is approved for adult and pediatric patients 12 years and older.
FDA Approves Mepolizumab for Treatment of COPD Exacerbations
Approval comes from positive results in the MATINEE and METREX phase III trials, with data showing a significant reduction in annual rates of COPD exacerbations among patients.
Automated Insulin Delivery System to Be Integrated with Glucose-Ketone Sensor
Insulin delivery technology company Sequel Med Tech announced its future partnership with Abbott’s glucose-ketone sensor, which is currently under development.
Evernorth Benefit Option Will Cap Wegovy, Zepbound Monthly Cost at $200
The new program aims to reduce costs for patients, with savings estimated at as much as $3600 per year.
Atopic Dermatitis Associated With Higher Dementia Risk
Through a comprehensive review and meta-analysis, researchers identified the correlation between atopic dermatitis and dementia.
FDA Will Make Importing Prescription Drugs From Canada Easier for States
Importing prescription drugs from Canada has been met with criticism, such as weakening the pharmaceutical supply chain and posing increased risks to patient safety.
CTx-1301 Demonstrates Improvements in ADHD Across 3 Dosages
Patients included in the study were aged 6 to 17 years with attention deficit/hyperactivity disorder (ADHD).
FDA Grants Interchangeability Designation to Ustekinumab-Aauz for Stelara
Pharmacists can substitute ustekinumab with the biosimilar at the pharmacy level, depending on their state laws.
Adult MTM Models for Children Could Improve Medication Costs, Effectiveness
Researchers investigate annual medication costs for children and determine which of them would qualify for medication therapy management based on CMS thresholds.
Deprescribing Leads to Reduction in Polypharmacy, Inappropriate Medication Use
Researchers aim to understand how deprescribing interventions impacted changes in inappropriate medication use or total prescription drugs among older, community-dwelling adults.
V116 Pneumococcal Vaccine Shows Noninferiority to PPSV23
V116 is noninferior to 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all 12 common serotypes and superior to 9 unique serotypes.
More Americans Now Believe MMR Vaccine Causes Autism vs 2021
Approximately 67% of adults in the US know that vaccines do not cause autism in children, declining significantly from 74% in 2021.
PCV24 Is Clinically, Economically Unfavorable Compared with PCV21
Researchers estimate the cost-effectiveness of PCV24 in the older adult population compared with the currently accepted pneumococcal vaccine schedules in the US.
Safeguarding Patient Health During Natural Disasters: Lessons from the Recent California Wildfires
Specialty pharmacies help support their continuity of care with practiced disaster response plans.
People with HIV Show Significantly Low Pneumococcal Vaccination Rates
Researchers wanted to better understand prescribing patterns of pneumococcal vaccines for people living with HIV in a tertiary care hospital.
Postmenopausal Women With Increased Stress at Higher Risk of Alzheimer Disease
However, there is no association between cortisol and tau pathology.
SSRIs Are Most Effective in Treatment of Skin-Picking Disorder
Researchers conduct a scoping review to update and determine what the best available options are for treating patients with skin-picking disorder.
Strategies for Independent Pharmacies to Harness Consumer Trends and Meet the Competition
Pharmacies face mounting challenges amid increased competition, rising operational costs, and complex reimbursement models.
Children With Skin Diseases Are at Higher Risk of Sleep Disorders
In children aged 5 to 17 with skin disorders, researchers explore the risk of developing psychosocial comorbidities, sleep disturbances, and common related symptoms.
GLP-1 Usage Does Not Increased Risk of Psychiatric Events, Study Finds
Glucagon-like peptide-1 receptor agonists have been associated with improvements in quality of life (QOL), restrained eating, and emotional eating behavior.
Q&A: Myths, Misinformation Surrounding Hepatitis Vaccines
Jeff Goad, PharmD, MPH, discusses hesitancy for hepatitis vaccines and the necessary advice pharmacists can utilize to help patients manage these misconceptions.
FDA Approves Nuvaxovid for the Prevention of COVID-19
Novavax’s COVID-19 vaccine has been available in the US under emergency use authorization since July 2022.
Suicide Risk Management Crucial in Dermatological Care
Researchers conducted a clinical review detailing the intersection of dermatology and suicide, explaining why skin conditions lead to increased risk of poor mental health.
Average Duration of ADHD Medication Is 3 Years for Children, Adolescents
Investigators note that the long-term effects of attention deficit/hyperactivity disorder (ADHD) medication for children remain lacking.
Rite Aid to Sell Pharmacy Assets From Over 1,000 Stores to CVS, Walgreens
The announcement comes shortly after the company announced it had filed its second chapter 11 bankruptcy in under 2 years.
Q&A: Vaccines Available to Protect Patients Against Hepatitis Viruses
Jeff Goad, PharmD, MPH, discusses hepatitis viruses and the current vaccination schedules available for patients to stay protected.
FDA Approves Dihydroergotamine as Auto Injectable for Migraine Treatment
Dihydroergotamine (Brekiya) is an acute treatment to help relieve migraine attacks, and it can come in nasal sprays, injections, and intravenous infusions.
Potential Universal Vaccine Could Prevent Swine, Human, and Bird Flu
The investigators hope to pursue a human vaccine in order to improve upon the already existing vaccines.
Q&A: What the Most-Favored-Nation Drug Pricing Executive Order Means for Community Pharmacy
Ronna Hauser, PharmD, Senior Vice President of Policy & Pharmacy Affairs at NCPA, provides insights into President Trump’s most recent executive order regarding manufacturer drug prices.
